Home › Merck and NewLink Genetics Enter Into Licensing and Collaboration Agreement for Investigational Ebola Vaccine
 

Keywords :   


Merck and NewLink Genetics Enter Into Licensing and Collaboration Agreement for Investigational Ebola Vaccine

2014-11-24 13:30:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J. & AMES, IA Clinical Development, Manufacturing Expertise, and Scale Critical to Success WHITEHOUSE STATION, N.J. & AMES, IA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NewLink Genetics Corporation (NASDAQ:NLNK), announced today that they have entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLinks investigational rVSV-EBOV (Ebola) vaccine candidate. Language: English Contact: Merck Media Contacts:Pam Eisele, 267-305-3558Imraan Munshi, 215-652-0059orInvestor Contacts:NewLink GeneticsJack Henneman, 515-598-2561orMerckJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: NLNK Exchange: NASDAQ read more

Tags: enter agreement collaboration licensing

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
04.07Tropical Depression One-E Graphics
04.07Tropical Depression One-E Forecast Discussion Number 1
04.07Tropical Depression One-E Wind Speed Probabilities Number 1
04.07Tropical Depression One-E Public Advisory Number 1
04.07Summary for Tropical Depression One-E (EP1/EP012024)
04.07Hurricane Beryl Graphics
04.07Tropical Depression One-E Forecast Advisory Number 1
04.07Hurricane Beryl Forecast Discussion Number 24
More »